Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.16 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.59 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -69.7 | |||||
| 3-Year EBITDA Growth Rate | 16.2 | |||||
| 3-Year EPS without NRI Growth Rate | 17.9 | |||||
| 3-Year FCF Growth Rate | 9.9 | |||||
| 3-Year Book Growth Rate | 23.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 426.56 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.82 | |||||
| 9-Day RSI | 53.35 | |||||
| 14-Day RSI | 51.22 | |||||
| 3-1 Month Momentum % | 17.12 | |||||
| 6-1 Month Momentum % | -58.06 | |||||
| 12-1 Month Momentum % | -61.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.66 | |||||
| Quick Ratio | 5.66 | |||||
| Cash Ratio | 5.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 1.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10972.94 | |||||
| Net Margin % | -5142.56 | |||||
| FCF Margin % | -9181.01 | |||||
| ROE % | -37.57 | |||||
| ROA % | -26.15 | |||||
| ROIC % | -185.86 | |||||
| 3-Year ROIIC % | 68.41 | |||||
| ROC (Joel Greenblatt) % | -484.6 | |||||
| ROCE % | -61.19 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 143.14 | |||||
| PB Ratio | 1.07 | |||||
| Price-to-Tangible-Book | 1.07 | |||||
| EV-to-EBIT | -0.51 | |||||
| EV-to-Forward-EBIT | -1.22 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Revenue | 56.08 | |||||
| EV-to-Forward-Revenue | 44.12 | |||||
| EV-to-FCF | -0.59 | |||||
| Price-to-GF-Value | 0.91 | |||||
| Price-to-Net-Current-Asset-Value | 1.93 | |||||
| Price-to-Net-Cash | 2.12 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -71.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OVID
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ovid Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.632 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | -0.36 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.08 | ||
| Volatility % | 91.29 | ||
| 14-Day RSI | 51.22 | ||
| 14-Day ATR ($) | 0.082376 | ||
| 20-Day SMA ($) | 1.106 | ||
| 12-1 Month Momentum % | -61.19 | ||
| 52-Week Range ($) | 0.68 - 4.1 | ||
| Shares Outstanding (Mil) | 71.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ovid Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ovid Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ovid Therapeutics Inc Frequently Asked Questions
What is Ovid Therapeutics Inc(OVID)'s stock price today?
The current price of OVID is $1.09. The 52 week high of OVID is $4.10 and 52 week low is $0.68.
When is next earnings date of Ovid Therapeutics Inc(OVID)?
The next earnings date of Ovid Therapeutics Inc(OVID) is 2025-03-07 Est..
Does Ovid Therapeutics Inc(OVID) pay dividends? If so, how much?
Ovid Therapeutics Inc(OVID) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers